75Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T, Semenza GL, Hirota K
(2004) Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK
and phosphatidylinositol 3-kinase signaling. J Biol Chem 279:2550–2558
Kelly D, Delday MI, Mulder I (2012) Microbes and microbial effector molecules in treatment of
inflammatory disorders. Immunol Rev 245:27–44
Kennedy A, Ng CT, Biniecka M, Saber T, Taylor C, O’Sullivan J, Veale DJ, Fearon U (2010)
Angiogenesis and blood vessel stability in inflammatory arthritis. Arthritis Rheum
62:711–721
Keunen O, Johansson M, Oudin A, Sanzey M, Abdul Rahim SA, Fack F, Thorsen F, Taxt T,
Bartos M, Jirik R, Miletic H, Wang J, Stieber D, Stuhr L, Moen I, Rygh CB, Bjerkvig R,
Niclou SP (2011) Anti-vascular endothelial growth factor treatment reduces blood supply and
increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA 108:3749–3754
Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O’Reilly
T, Lane H, Susa M (2004) Everolimus suppresses cancellous bone loss, bone resorption, and
cathepsin K expression by osteoclasts. Bone 35:1144–1156
Lala PK, Chakraborty C (2001) Role of nitric oxide in carcinogenesis and tumour progression.
Lancet Oncol 2:149–156
Laragione T, Gulko PS (2010) mTOR regulates the invasive properties of synovial fibroblasts in
rheumatoid arthritis. Mol Med 16:352–358
Luross JA, Williams NA (2001) The genetic and immunopathological processes underlying col-
lagen-induced arthritis. Immunology 103:407–416
Maxwell JR, Gowers IR, Moore DJ, Wilson AG (2010) Alcohol consumption is inversely associ-
ated with risk and severity of rheumatoid arthritis. Rheumatology 42:508–514
McDevitt H (2000) A new model for rheumatoid arthritis? Arthritis Res 2:85–89
Moran EM, Heydrich R, Ng CT, Saber TP, McCormick J, Sieper J, Appel H, Fearon U, Veale DJ
(2011) IL-17A expression is localised to both mononuclear and polymorphonuclear synovial
cell infiltrates. PLoS ONE 6:e24048
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson
JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A;
RECORD-1 Study Group. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a
double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449-456
Muntan J, De la Mat M (2010) Nitric oxide and cancer. World J Hepatol 2:337–344
Nagy G, Clark JM, Buzas E, Gorman C, Cope AP (2007) Nitric oxide, chronic inflammation and
autoimmunity. Immunol Lett 111:1–5
Nagy G, Clark JM, Buzas E, Gorman C, Pasztoi M, Koncz A, Falus A, Cope AP (2008) Nitric
oxide production of T lymphocytes is increased in rheumatoid arthritis. Immunol Lett
118:55–58
Nagy G, Koncz A, Telarico T, Fernandez D, Ersek B, Buzas E, Perl A (2010) Central role of NO
in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res
Ther 12:210
Natarajan R, Fisher BJ, Fowler AA III (2003) Regulation of hypoxia inducible factor-1 by nitric
oxide in contrast to hypoxia in microvascular endothelium. FEBS Lett 549:99–104
Ng CT, Biniecka M, Kennedy A, McCornick J, FitzGerald O, Bresnihan B, Buggy D, Taylor CT,
O’Sullivan J, Fearon U, Veale DJ (2010) Synovial tissue hypoxia and inflammatory inflam-
mation in vivo. Ann Rheum Dis 69:1389–1395
Nisoli E, Carruba MO (2006) Nitric oxide and mitochondrial biogenesis. J Cell Sci
119:2855–2862
Olson N, van der Vliet A (2011) Interactions between nitric oxide and hypoxia inducible factor
signaling pathways in inflammatory disease. Nitric Oxide 25:125–137
Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J,
Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal
cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer
109:2257–2267